Jump to content
Content on WikiMesothelioma is reviewed prior to publication by three named attorneys at Danziger & De Llano LLP. Dr. Luciano Mutti, MD, PhD, co-author of the European mesothelioma treatment guidelines, serves as the site's Medical Reviewer. See our editorial standards.

Understanding Your Diagnosis

From WikiMesothelioma — Mesothelioma Knowledge Base


Diagnosis Quick Facts
Key numbers every patient should know
Annual Cases 2,669 in U.S. in 2022 (all sites)[1]
Most Common Pleural (81% of U.S. cases, 2003-2022)[1]
Latency Period Several decades; median 44.6 years in Italy's national registry[2]
Best Prognosis Epithelioid (14 mo. median in SEER stage I-III pleural cases, 2004-2010)[3]
Trust Fund Median $41,000 per mesothelioma claim (26 largest trusts, through 2008)[4]
Trust Assets Reported ~$30 billion as of year-end 2008[4]

Executive Summary

A mesothelioma diagnosis represents one of life's most challenging moments, but understanding your specific diagnosis is the first step toward making informed decisions about treatment and legal compensation. In the United States, 2,669 new mesothelioma cases of all sites were reported in 2022, and pleural mesothelioma accounted for 81.0% of cases reported from 2003 to 2022.[1] Age-standardized U.S. incidence fell 33% (from 0.64 to 0.43 per 100,000) and mortality 31% between 1990 and 2023, with much steeper declines among men than women, while the absolute numbers of cases and deaths rose.[5] Your pathology report contains critical information that guides both medical treatment options and legal claim strategies, including the type, cell type, and stage of your cancer. Outcomes vary widely by cell type and stage: in a single-institution series of 355 consecutive patients undergoing pleurectomy/decortication, median overall survival was 20.7 months, rising to 69.8 months in the subgroup with T1-stage, epithelioid-histology disease; these are selected surgical patients, not a prediction for an individual.[6] A 2024 phase 3 randomized trial found that adding extended pleurectomy/decortication to chemotherapy did not improve survival over chemotherapy alone[7]; experts disagree about how that trial should be interpreted.[8]

At a Glance

  • Pleural vs peritoneal — in U.S. registry data for 2003-2022, 81.0% of mesotheliomas arose in the pleura (lung lining) and 11.1% in the peritoneum (abdominal lining); the peritoneal share was higher in women (20.5%) than in men (8.1%)[1]
  • Survival differs sharply by cell type — among 1,183 stage I-III pleural mesothelioma patients in the SEER database (2004-2010), median overall survival was 14 months for epithelioid histology, 10 months for biphasic and 4 months for sarcomatoid[3]
  • Surgical series vs randomized evidence — median survival after pleurectomy/decortication was 20.7 months across 355 consecutive patients at one institution and 69.8 months for those with T1-stage epithelioid disease, figures that reflect patient selection.[6] In the 2024 MARS 2 randomized trial, extended pleurectomy decortication added to chemotherapy was associated with worse survival to 2 years and more serious adverse events than chemotherapy alone[7]; experts disagree about how that trial should be interpreted.[8]
  • Surgery for selected patients only — only selected patients are candidates for radical surgery, and guidelines advise that patients considered for multimodal treatment including radical surgery be treated within clinical trials in dedicated centres[9]
  • Decades-long latency — mesothelioma typically appears several decades after first asbestos exposure; in the Western Australian Mesothelioma Registry the median latency was 47 years and the median age at diagnosis was 70[10]
  • Peritoneal outcomes vary widely — in a 401-patient multi-institutional registry of patients selected for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), median overall survival was 53 months, with 5-year survival of 47%.[11] Across all U.S. peritoneal cases in the SEER-18 registry (2000-2018), overall median age-standardized survival was 11.6 months[12]
  • ~$30 billion in trust assets reported as of year-end 2008 — RAND counted 56 asbestos bankruptcy trusts paying mesothelioma claims in that analysis[4]
  • Multiple compensation paths — patients can pursue trust funds, litigation settlements, and VA benefits simultaneously rather than choosing one[13]

Why Understanding Your Diagnosis Matters

Every detail in your pathology report serves a purpose beyond medical jargon. The type of mesothelioma determines which surgical options may be available. The cell type significantly influences your prognosis and response to treatment. The stage indicates how far the cancer has spread and directly impacts treatment decisions.[14] For legal purposes, these same details establish the severity of your condition — which affects both the urgency of your claim and the compensation you may receive.[15] Patients with a clear understanding of their diagnosis can make better-informed decisions about both their medical care and their legal options. This knowledge transforms you from a passive recipient of care into an active participant in decisions that affect your life and your family's financial security.

Key Facts

Metric Finding
Annual Diagnoses 2,669 new mesothelioma cases of all sites were reported in the United States in 2022; the figure is often rounded to about 3,000 a year[1]
Most Common Type Pleural mesothelioma (lung lining): 81.0% of U.S. cases reported from 2003 to 2022[1]
Latency Period Typically several decades between first asbestos exposure and diagnosis; a pooled review estimated the median latent period at at least 32 years[16]
Age at Diagnosis Median age 70 years at diagnosis in the Western Australian Mesothelioma Registry, reflecting decades between exposure and disease[10]
Cell Type Impact Epithelioid cell type carries the best prognosis of the three histologies: median overall survival of 14 months among stage I-III pleural mesothelioma patients in SEER (2004-2010), versus 4 months for sarcomatoid[3]
Staging Significance Only selected patients are candidates for radical surgery; systemic therapy is used for unresectable disease at any stage[9]
Trust Fund Compensation A mesothelioma diagnosis qualifies for the highest disease level under most trust distribution procedures. Each trust pays a published percentage of the scheduled value it assigns that claim, so combined recovery is the sum across every qualifying trust rather than a fixed amount; across the 26 largest trusts the median payment on a mesothelioma claim through 2008 was $41,000[4]
Documentation Importance Complete pathology reports essential for both treatment planning and legal claim success
Survival by Site and Treatment Figures from selected surgical series and from population registries are not comparable. In a 401-patient registry of peritoneal mesothelioma selected for cytoreductive surgery plus HIPEC, median overall survival was 53 months.[11] Across 1,183 stage I-III pleural mesothelioma patients in SEER (2004-2010), median overall survival was 14 months for epithelioid histology[3]
Total Trust Funds RAND counted 56 asbestos bankruptcy trusts, which reported assets of approximately $30 billion as of year-end 2008[4]

What Does a Mesothelioma Diagnosis Mean?

Receiving a mesothelioma diagnosis means that doctors have identified cancerous cells in the mesothelium, the protective membrane that lines many of your body's internal organs. Exposure to asbestos causes most mesotheliomas.[17] The disease typically appears several decades after first exposure; in Italy's national mesothelioma register the median latency was 44.6 years.[2] The mesothelium functions like a protective wrapping around your lungs, heart, and abdominal cavity, allowing organs to move smoothly against surrounding structures.

When asbestos fibers become embedded in mesothelial tissue, they cause decades of chronic inflammation and genetic damage that eventually transforms healthy cells into cancer. Understanding this connection between your past asbestos exposure and your current diagnosis is crucial for both medical treatment planning and establishing the foundation for legal compensation claims.[18]

"The long latency period between asbestos exposure and diagnosis means that patients diagnosed today were often exposed during employment 30, 40, or even 50 years ago. Identifying and documenting that historical exposure is essential for pursuing all available compensation options."
— Paul Danziger, Founding Partner, Danziger & De Llano
Did You Know: The connection between asbestos and mesothelioma is so well-established that virtually every confirmed case qualifies for some form of compensation. Multiple trust funds, legal claims, and — for veterans — VA benefits may all be available simultaneously.[13]

What Are the Four Types of Mesothelioma?

Type Percentage Location Treatment Outlook
Pleural 81% (U.S., 2003-2022)[1] Lung lining (pleura) Systemic therapy for most patients; surgery only for selected patients. In the 2024 MARS 2 trial, adding extended pleurectomy decortication to chemotherapy was associated with worse survival to 2 years[7]; experts disagree about how that trial should be interpreted[8]
Peritoneal 11% (U.S., 2003-2022)[1] Abdominal lining (peritoneum) Wide range of outcomes. In a 401-patient registry of patients selected for cytoreductive surgery plus HIPEC, median overall survival was 53 months (5-year survival 47%).[11] Across all U.S. peritoneal cases in SEER-18 (2000-2018), overall median age-standardized survival was 11.6 months[12]
Pericardial 0.2% (U.S., 2003-2022)[1] Heart lining (pericardium) Limited options due to location. Among 41 primary pericardial mesothelioma patients in SEER (1973-2015), median overall survival was 2 months[19]
Testicular 0.2% (U.S., 2003-2022)[1] Tunica vaginalis (testes) One of the rarest forms. In Italy's national mesothelioma registry (1993-2015), median survival was 33.0 months for tunica vaginalis testis mesothelioma[20]

Pleural Mesothelioma: The Most Common Diagnosis

Pleural mesothelioma develops in the pleura, the two-layer membrane surrounding the lungs, and accounted for 81.0% of U.S. mesothelioma cases reported from 2003 to 2022.[1] The pleura consists of a visceral layer directly covering the lung surface and a parietal layer lining the chest cavity, with a small amount of lubricating fluid between them enabling smooth breathing movements.[21]

Common symptoms of pleural mesothelioma include persistent shortness of breath, chest pain that worsens with deep breathing, unexplained weight loss, and chronic dry cough. These symptoms develop as tumors thicken the pleural membranes and fluid accumulates in the chest cavity, compressing lung tissue. Diagnosis typically involves imaging scans followed by a tissue biopsy to confirm the presence of malignant mesothelioma cells.

Only selected patients are candidates for radical surgery such as pleurectomy/decortication (P/D), and guidelines advise that patients considered for multimodal treatment including radical surgery be treated as part of clinical trials in dedicated centres.[9] In a single-institution series of 355 consecutive patients, median overall survival after P/D was 20.7 months, reaching 69.8 months in patients with both T1-stage disease and epithelioid histology; these figures reflect patient selection.[6] The value of the surgery itself remains contested: the 2024 MARS 2 phase 3 randomized trial found that extended P/D added to chemotherapy produced shorter median survival than chemotherapy alone (19.3 vs. 24.8 months) and more than three times the rate of serious adverse events.[7] The mesothelioma surgical community has not been unanimous about how to interpret the trial: a published expert perspective, facilitated by Harvey Pass, set out arguments for and against its conclusions, including issues of histologic subtype selection, the timing of randomization and the use of preoperative staging.[8] A 2026 statistical sensitivity analysis of both MARS trials, published as a journal pre-proof, questioned how robust their findings are: the MARS 2 survival difference would no longer be statistically significant if 71 of the trial's 335 patients (21%), all from the surgery group, had instead had the same restricted mean survival as patients given chemotherapy alone.[22] Its authors concluded that additional studies may come to opposite conclusions favoring surgery and that more trials are needed, while noting that there is no universally accepted benchmark for how robust such a result must be.[22] For unresectable disease, first-line systemic therapy is the usual treatment. Nivolumab plus ipilimumab has been approved in the USA since October 2020 for previously untreated unresectable pleural mesothelioma.[23] In a separate phase 3 trial, adding pembrolizumab to platinum-pemetrexed chemotherapy lengthened median overall survival from 16.1 to 17.3 months.[24] In the earlier MAPS phase 3 trial of 448 patients, adding bevacizumab to cisplatin plus pemetrexed lengthened median overall survival from 16.1 to 18.8 months, with more grade 3 or higher hypertension and thrombotic events.[25] Palliative and supportive care are provided alongside treatment, and treatment decisions belong to the patient's oncology team.

Peritoneal Mesothelioma: The Second Most Common Type

Peritoneal mesothelioma affects the peritoneum, the membrane lining the abdominal cavity, and accounted for 11.1% of U.S. mesothelioma cases reported from 2003 to 2022 (8.1% of cases in men and 20.5% in women).[1]

Symptoms often include abdominal pain and swelling, changes in bowel habits, unexplained weight loss, and fluid accumulation in the abdomen (ascites). Because these symptoms mimic common digestive conditions, the diagnosis of peritoneal mesothelioma is often made late.

Good News: Some patients with peritoneal mesothelioma live far longer than population figures suggest. Among patients selected for cytoreductive surgery combined with HIPEC (hyperthermic intraperitoneal chemotherapy), a 401-patient multi-institutional registry reported median overall survival of 53 months, with 3-year survival of 60% and 5-year survival of 47%. Survival was better for patients with epithelial-subtype tumors, no lymph node involvement, and complete or near-complete cytoreduction, so individual outcomes vary widely within that figure.[11] Across all U.S. peritoneal cases in SEER-18 (2000-2018), which include patients who could not have this surgery, overall median age-standardized survival was 11.6 months.[12]

Pericardial Mesothelioma: Rare Heart Lining Cancer

Pericardial mesothelioma develops in the pericardium, the protective sac surrounding the heart, and represents less than 2% of all mesotheliomas.[26] This extremely rare form presents unique challenges because symptoms including chest pain, irregular heartbeat, difficulty breathing, and fatigue closely mimic common cardiac conditions.

The rarity of pericardial mesothelioma often delays accurate diagnosis, with some cases not identified until autopsy. Treatment options are limited due to the tumor's proximity to the heart, though palliative procedures like pericardiocentesis (draining excess fluid) can provide symptomatic relief. Reported survival is short: in a population-based analysis of 41 primary pericardial mesothelioma patients identified in the SEER program between 1973 and 2015, median overall survival was 2 months and one-year survival was 22.0%.[19] That cohort spans four decades of diagnosis and treatment, so it should be read as the population-level picture across that period rather than a present-day expectation for an individual patient.

From a legal perspective, pericardial mesothelioma cases often receive higher compensation due to the aggressive nature of the disease and limited treatment options. Exposure to asbestos causes most mesotheliomas,[17] and courts and trust funds generally recognize the devastating nature of this diagnosis.[15]

Testicular Mesothelioma: The Rarest Form

Testicular mesothelioma (mesothelioma of the tunica vaginalis), developing in the tunica vaginalis membrane covering the testes, is one of the rarest forms; a systematic review of the literature from 1982 through March 2024 identified 289 reported cases.[27] This type typically presents as a painless mass or swelling in the scrotum and is often initially mistaken for more common conditions like hydrocele or hernia.

Survival is variable: in Italy's national mesothelioma registry (1993-2015), median survival was 33.0 months for tunica vaginalis testis mesothelioma.[20] Radical surgery with orchiectomy was the most frequent treatment in the review of 289 cases; a minority of patients received adjuvant therapy after surgery, with no evidence of survival improvement.[27]

How Does Mesothelioma Cell Type Affect Your Prognosis?

Your pathology report will identify the cell type of your mesothelioma, which significantly impacts both prognosis and treatment options. Three primary cell types exist: epithelioid, sarcomatoid, and biphasic (a combination of both).[28]

Cell Type Frequency Median Survival Key Characteristics
Epithelioid 69% (811 of 1,183)[3] 14 months (SEER stage I-III, 2004-2010)[3] Most favorable prognosis of the three cell types
Sarcomatoid 19% (224 of 1,183)[3] 4 months (SEER stage I-III, 2004-2010)[3] Shortest survival of the three cell types
Biphasic 12% (148 of 1,183)[3] 10 months (SEER stage I-III, 2004-2010)[3] A larger sarcomatoid component is associated with shorter survival

Epithelioid Mesothelioma

Epithelioid mesothelioma is the most common histology and carries the most favorable prognosis. Among 1,183 stage I-III pleural mesothelioma patients in the SEER database from 2004 to 2010, 811 (69%) were epithelioid, and their median overall survival was 14 months; among the subset who underwent cancer-directed surgery it was 19 months.[3] Longer survival has been reported in selected surgical series: in 355 consecutive patients undergoing pleurectomy/decortication at a single institution, those with T1-stage epithelioid disease had a median overall survival of 69.8 months and five-year survival of 54.1%, against 20.7 months for the intent-to-treat cohort as a whole.[6] Those series describe selected patients: in the 2024 MARS 2 randomized trial, extended pleurectomy decortication added to chemotherapy was associated with worse survival to 2 years than chemotherapy alone[7]; experts disagree about how that trial should be interpreted.[8]

Sarcomatoid Mesothelioma

Sarcomatoid mesothelioma carries the least favorable prognosis of the three histologies. It accounted for 224 of 1,183 stage I-III pleural mesothelioma patients (19%) in SEER from 2004 to 2010, with a median overall survival of 4 months — and 4 months again in the subset who underwent cancer-directed surgery, one of the findings that led the authors to conclude surgery may not benefit this group.[3] A sarcomatoid diagnosis is not a reason to forgo treatment. For unresectable disease, first-line systemic therapy is used: nivolumab plus ipilimumab has been approved in the USA since October 2020 for previously untreated unresectable pleural mesothelioma.[23] In the five-year update of that trial, 14% of patients given nivolumab plus ipilimumab were alive at five years, against 6% with chemotherapy.[29] Chemotherapy with bevacizumab is another first-line option here: the MAPS trial stratified patients by histology,[25] and NCCN guidelines list platinum plus pemetrexed with or without bevacizumab as category 1 first-line therapy, as a preferred option for epithelioid disease and an other recommended option for biphasic or sarcomatoid disease.[30] Symptom management and palliative care are provided alongside treatment, and treatment decisions belong to the patient's oncology team.

Biphasic Mesothelioma

Biphasic mesothelioma contains both epithelioid and sarcomatoid cells. It accounted for 148 of 1,183 stage I-III pleural mesothelioma patients (12%) in SEER from 2004 to 2010, with a median overall survival of 10 months, between the epithelioid and sarcomatoid groups.[3] In an international expert-panel study, a sarcomatoid component of less than 80% correlated with better survival, and agreement between expert pathologists on biphasic diagnoses was only moderate (weighted kappa 0.45), so expert pathology review is advisable.[31]

What Do the Stages of Mesothelioma Mean for Your Treatment?

Mesothelioma staging describes how far your cancer has spread and directly impacts available treatment options.[14] In the TNM system for pleural mesothelioma, the T category is based on pleural involvement and extent of invasion, N describes lymph node involvement and M describes distant metastasis; proposals for the ninth edition add measured pleural thickness to the T category.[32]

"Understanding your cancer stage is essential not only for treatment planning but also for pursuing expedited legal processes when appropriate. Patients with advanced diagnoses may qualify for accelerated claim procedures that provide compensation faster."
— Rod De Llano, Founding Partner, Danziger & De Llano
Stage Description (IASLC 8th edition) Treatment Options
Stage 1 No lymph node spread; tumor ranges from T1 to T3 (stage IA T1N0; stage IB T2-3N0) Systemic therapy for most patients; surgery considered only for selected patients, preferably within clinical trials at experienced centres
Stage 2 Spread to lymph nodes on the same side (T1-2N1) Systemic therapy is typically first-line; surgery only in highly selected patients
Stage 3 T3 tumor with N1 nodes (stage IIIA), or N2 nodes or a locally advanced T4 tumor (stage IIIB) Systemic therapy (chemotherapy; nivolumab plus ipilimumab)
Stage 4 Any distant metastasis (M1) Systemic therapy (chemotherapy or nivolumab plus ipilimumab), with palliative and supportive care alongside; clinical trials

Stage groups follow the IASLC eighth edition: stage IA (T1N0), stage IB (T2-3N0), stage II (T1-2N1), stage IIIA (T3N1), stage IIIB (T1-3N2 or any T4) and stage IV (any M1).[33] Stage is one of several prognostic factors, alongside histology, age and general health, and survival figures by stage come from selected cohorts, differ between staging editions and describe groups rather than individuals. Among patients diagnosed with pleural mesothelioma between 2004 and 2020 in the U.S. National Cancer Database, median overall survival was 10.3 months from diagnosis.[34]

What We Handle vs. What You Focus On

  • All trust fund paperwork and filings[35]
  • Insurance claim appeals and denials
  • VA benefits applications[13]
  • Settlement negotiations
  • Court filings if needed
  • Coordination between all compensation sources
  

What You Focus On

  • Treatment decisions with your doctors
  • Time with family and loved ones
  • Recovery and quality of life
  • Answering questions about work history
  • Providing documents you already have
  • Peace of mind knowing experts handle the rest

Essential Documents Checklist

Documents to Gather for Your Claim
* Pathology Report — Including immunohistochemistry confirming mesothelioma diagnosis
* Employment History — Names, dates, and locations of all employers where asbestos exposure may have occurred[18]
* Military Service Records — DD-214, service dates, duty stations, MOS/rating (for veterans)
* Medical Records — All imaging studies, treatment plans, and physician notes
* Witness Information — Contact details for coworkers who can verify exposure conditions
* Insurance Information — Current health insurance cards and policy details[21]

Frequently Asked Questions

How long does it take to get a mesothelioma diagnosis confirmed?

Published measurements are limited and vary by health system. In a study of 66 patients at one tertiary centre in Brazil, the median time from symptom onset to the first specialist visit was 6.5 months, and from the specialist visit to histological diagnosis 1.5 months.[36] The process involves imaging scans (CT, MRI, or PET), followed by a tissue biopsy that a pathologist examines under a microscope. Immunohistochemistry staining is usually required to distinguish mesothelioma from other cancers, which can add additional days to the timeline.[37]

Can mesothelioma be misdiagnosed?

Yes. Its symptoms resemble more common conditions, and the pathology diagnosis itself can be difficult. No study has established how often mesothelioma is mislabelled before a biopsy is taken. When expert panels in France's national surveillance program reviewed locally made pathology diagnoses, the initial diagnosis was confirmed in 67% of cases and ruled out in 13%.[38] In a review of 92 diagnoses at two reference centers in eastern China, the diagnosis was confirmed in 12 of 34 pleural tumors.[39] For this reason, expert pathology review following the International Mesothelioma Interest Group guidelines is advisable.[40]

Cell type can influence the urgency and value of your legal claim. Sarcomatoid mesothelioma, with its shorter prognosis, may qualify for expedited legal processes including accelerated depositions and faster trust fund processing. Courts recognize the time-sensitive nature of aggressive diagnoses and may prioritize these cases accordingly.[15]

What is the difference between Stage 1 and Stage 4 mesothelioma?

Stage 1 means the cancer has not spread to lymph nodes; only selected patients are candidates for radical surgery, which guidelines advise within clinical trials in dedicated centres.[9] Stage 4 means the cancer has spread to distant sites. It is treated with systemic therapy such as nivolumab plus ipilimumab, approved in the USA since October 2020 for previously untreated unresectable pleural mesothelioma,[23] with palliative care alongside and clinical trials as further options. Survival statistics by stage describe groups of patients, not individuals.

How does my diagnosis affect trust fund compensation?

A confirmed mesothelioma diagnosis qualifies you for the highest disease classification (Level 8) under most asbestos trust fund payment schedules. Each trust pays a published percentage — its payment percentage — of the scheduled value it assigns a qualifying claim, so what you recover from the trust system is the sum of what several trusts pay rather than a single fixed figure per trust. Across the 26 largest trusts, RAND reported a median payment percentage of 25% (range 1.1%–100%) and a median payment of $41,000 per mesothelioma claim; those trusts had paid $10.9 billion on 2.4 million claims of all disease types through 2008, and reported assets of approximately $30 billion as of year-end 2008.[4]

Should I get a second opinion on my mesothelioma diagnosis?

A second opinion can help. Because the pathology of mesothelioma is difficult, the International Mesothelioma Interest Group publishes guidelines for its diagnosis,[40] and review by a pathologist and multidisciplinary team experienced with mesothelioma can help confirm the histology and cell type. This matters because treatment plans and prognosis vary with cell type and stage. GRACE (Global Resource for Advancing Cancer Education) provides free, expert-reviewed cancer education directly to patients and caregivers, with a Learn More patient education hub that covers rare cancers including thoracic malignancies — a useful supplement when researching diagnosis, treatment options, and clinical trial considerations alongside your mesothelioma specialist's guidance.[41]

Can veterans with mesothelioma file both VA and trust fund claims?

Yes, veterans with mesothelioma can pursue VA disability benefits and asbestos trust fund claims simultaneously, along with personal injury litigation. These compensation sources are legally independent and do not offset each other. Many veterans exposed during military service in shipyards, engine rooms, or construction are eligible for multiple forms of compensation.[13]

What should I do immediately after receiving a mesothelioma diagnosis?

After diagnosis, prioritize three actions: (1) seek evaluation by a team experienced in treating mesothelioma, (2) contact an experienced mesothelioma attorney to protect your legal rights before filing deadlines expire, and (3) begin gathering documentation of your asbestos exposure history including employment records, military service records, and witness contacts.[18]

Quick Statistics

  • 31,908 new cases worldwide in 2021 — Global Burden of Disease estimate, about double the 1990 figure; the United Kingdom and Australia had the highest age-standardized rates[42]
  • About three in four cases in men — men accounted for 47,973 of the 63,620 U.S. mesothelioma cases reported from 2003 to 2022, largely reflecting occupational exposure[1]
  • Declining U.S. rates — the rate of new mesothelioma cases is going down because fewer people are exposed to asbestos[1]
  • Global burden — worldwide incident cases roughly doubled between 1990 (16,493) and 2021 (31,908) in Global Burden of Disease estimates[42]
  • Immunotherapy advances — nivolumab plus ipilimumab has been approved in the USA since October 2020 for previously untreated unresectable pleural mesothelioma[23]
  • No proven screening test — blood tests such as soluble mesothelin have been tried in asbestos-exposed people without proving useful for screening; in one cohort of 538 exposed people, no one was diagnosed with mesothelioma and a high false-positive rate was observed[43]
  • Diagnostic difficulty — expert panels in France's national surveillance program confirmed 67% of locally made pathology diagnoses and ruled out 13%[38]
  • 289 reported cases (1982–March 2024) — testicular mesothelioma (mesothelioma of the tunica vaginalis) is one of the rarest forms of mesothelioma; a systematic review of the literature from 1982 through March 2024 identified 289 reported cases[27]
  • Statute of limitations — filing deadlines vary by state, typically 1-6 years from diagnosis date, making early legal consultation critical[15]

If you or a loved one has been diagnosed with mesothelioma, resources are available:

Medically reviewed by Dr. Luciano Mutti, MD, PhD — Professor of Oncology, UniCamillus, Rome · Medical Oncology
Last reviewed: 2026-10-01 · Medical review covers clinical accuracy only and is not an endorsement of any legal service. See Editorial Standards for our editorial process.

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 Incidence of Malignant Mesothelioma, United States, 2003-2022, U.S. Cancer Statistics, Centers for Disease Control and Prevention, updated September 10, 2025.
  2. ↑ 2.0 2.1 Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer. 2007;43(18):2722-8. PMID 17980576.
  3. ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 Meyerhoff RR, Yang CF, Speicher PJ, Gulack BC, Hartwig MG, D'Amico TA, Harpole DH, Berry MF. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015;196(1):23-32. PMID 25791825.
  4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 Dixon L, McGovern G. Asbestos Bankruptcy Trusts and Tort Compensation, RAND Institute for Civil Justice, Monograph MG-1104, August 2011. States that trusts, "as of year-end 2008, reported assets of approximately $30 billion"; reports a median payment percentage of 25% (range 1.1%–100%) and a median payment of $41,000 per mesothelioma claim across the 26 largest trusts, which had paid $10.9 billion on 2.4 million claims through 2008.
  5. ↑ Geographic, Temporal, and Sex-Specific Trends in Mesothelioma Burden in the United States, 1990-2023. JCO Glob Oncol. 2026;12:e2600056. PMID 42275613.
  6. ↑ 6.0 6.1 6.2 6.3 Pleurectomy Decortication in the Treatment of Malignant Pleural Mesothelioma: Encouraging Results and Novel Prognostic Implications Based on Experience in 355 Consecutive Patients., Lapidot M, Gill RR, Mazzola E, et al, Ann Surg, 2022. PMID 33278174.
  7. ↑ 7.0 7.1 7.2 7.3 7.4 Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial, Lim E, Waller D, Lau K, et al., The Lancet Respiratory Medicine 2024;12(6):457-466, PMID: 38740044
  8. ↑ 8.0 8.1 8.2 8.3 8.4 A Perspective on the MARS2 Trial. J Thorac Oncol. 2025;20(3):262-272. PMID 39772349.
  9. ↑ 9.0 9.1 9.2 9.3 ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1900953. PMID 32451346.
  10. ↑ 10.0 10.1 The Western Australian Mesothelioma Registry: Analysis of 60 years of cases. Respirology. 2024;29(4):288-294. PMID 38153786.
  11. ↑ 11.0 11.1 11.2 11.3 Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237-42. PMID 19917862. "The overall median survival was 53 months (1 to 235 months), and 3- and 5-year survival rates were 60% and 47%, respectively."
  12. ↑ 12.0 12.1 12.2 Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States. Cancers (Basel). 2022;15(1):229. PMID 36612225.
  13. ↑ 13.0 13.1 13.2 13.3 Asbestos-Related Diseases — Mesothelioma Lawyer Center
  14. ↑ 14.0 14.1 Mesothelioma Staging Guide — Mesothelioma.net
  15. ↑ 15.0 15.1 15.2 15.3 Mesothelioma Case Value Information — Danziger & De Llano
  16. ↑ Latent period for malignant mesothelioma of occupational origin. J Occup Med. 1992;34(7):718-21. PMID 1494965.
  17. ↑ 17.0 17.1 Asbestos Exposure and Cancer Risk, National Cancer Institute.
  18. ↑ 18.0 18.1 18.2 Asbestos Exposure Information — Danziger & De Llano
  19. ↑ 19.0 19.1 Brydges H, Yin K, Balasubramaniyan R, Lawrence KW, Luo R, Karlson KJ, McAneny DB, Edwards NM, Reardon MJ, Dobrilovic N. Primary Pericardial Mesothelioma: A Population-Based Propensity Score-Matched Analysis. Semin Thorac Cardiovasc Surg. 2022;34(3):1113-1119. PMID 34320396.
  20. ↑ 20.0 20.1 Association between asbestos exposure and pericardial and tunica vaginalis testis malignant mesothelioma: a case-control study and epidemiological remarks. Scand J Work Environ Health. 2020;46(6):609-617. PMID 32253443.
  21. ↑ 21.0 21.1 Pleural Effusion Information — Mesothelioma Lawyer Center
  22. ↑ 22.0 22.1 Re-Evaluating MARS1 and MARS2: Should the Trials Guide Treatment Choice for Pleural Mesothelioma?, Cher BAY, Lin Q, Frank KA, Maloney JD, Balentine CJ, Axtell AL, Annals of Thoracic Surgery Short Reports 2026 (journal pre-proof, accepted 8 September 2026; not yet the Version of Record), DOI: 10.1016/j.atssr.2026.09.025
  23. ↑ 23.0 23.1 23.2 23.3 Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386. PMID 33485464.
  24. ↑ Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023;402(10419):2295-2306. PMID 37931632.
  25. ↑ 25.0 25.1 Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405-1414. PMID 26719230.
  26. ↑ Arrossi AV. Pericardial Mesotheliomas. Adv Anat Pathol. 2023;30(4):253-258. PMID 37104724. States that primary pericardial mesothelioma "has an incidence of <0.05% and comprises <2% of all mesotheliomas."
  27. ↑ 27.0 27.1 27.2 Mesothelioma of the Tunica Vaginalis Testis: Diagnostic and Therapeutic Management. A Comprehensive Review, 1982-2024., Stella S, Ceresoli GL, Dallari B, et al, Cancers (Basel), 2024. PMID 39682143.
  28. ↑ Mesothelioma Types Overview — MesotheliomaAttorney.com
  29. ↑ Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. J Clin Oncol. 2026;44(9):742-749. PMID 41734361.
  30. ↑ Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology., J Natl Compr Canc Netw 2026;24(8):e260038. PMID 42607715.
  31. ↑ New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center. J Thorac Oncol. 2018;13(8):1189-1203. PMID 29723687.
  32. ↑ The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for Revisions of the "T" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024;19(9):1310-1325. PMID 38521202.
  33. ↑ The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. J Thorac Oncol. 2016;11(12):2112-2119. PMID 27687962.
  34. ↑ Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database. Cancer Med. 2023;12(11):12208-12220. PMID 37062067.
  35. ↑ Trust Fund Payouts Guide — Danziger & De Llano
  36. ↑ Mesothelioma in a developing country: a retrospective analysis of the diagnostic process. J Bras Pneumol. 2022;48(5):e20220064. PMID 36000688.
  37. ↑ Pleural Mesothelioma Overview — Mesothelioma.net
  38. ↑ 38.0 38.1 The French National Mesothelioma Surveillance Program. Occup Environ Med. 2006;63(6):390-5. PMID 16469823.
  39. ↑ Improving the Accuracy of Mesothelioma Diagnosis in China. J Thorac Oncol. 2017;12(4):714-723. PMID 28007630.
  40. ↑ 40.0 40.1 Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2024;148(11):1251-1271. PMID 38586983.
  41. ↑ Learn More — Patient Education Hub, GRACE (Global Resource for Advancing Cancer Education)
  42. ↑ 42.0 42.1 The global burden of mesothelioma and its association with asbestos bans, 1990-2021: a population-based study. Lung Cancer. 2025;203:108534. PMID 40215614.
  43. ↑ Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med. 2008;178(8):832-7. PMID 18583574.

This information is provided for educational purposes and does not constitute medical or legal advice. Always consult qualified healthcare providers for medical decisions and experienced mesothelioma attorneys for legal guidance.


Retrieved from "https://wikimesothelioma.com/w/index.php?title=Understanding_Your_Diagnosis&oldid=5028"